Received Feb 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | LN75D | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 2A755 | — |
Menveo in 2022 and another dose of Menveo; Boostrix in 2022 and then received another dose of Boostrix; This non-serious case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too long in a 14-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number LN75D, expiry date 30-SEP-2025) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) (batch number 2A755, expiry date 28-OCT-2025) for prophylaxis. Previously administered products included Boostrix (in 2022) and Menveo (in 2022). On 22-JAN-2025, the patient received Menveo and Boostrix. On 22-JAN-2025, an unknown time after receiving Menveo and not applicable after receiving Boostrix, the patient experienced drug dose administration interval too long (Verbatim: Menveo in 2022 and another dose of Menveo) and drug dose administration interval too short (Verbatim: Boostrix in 2022 and then received another dose of Boostrix). The outcome of the drug dose administration interval too long and drug dose administration interval too short were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 22-JAN-2025 The patient received a dose of Menveo and Boostrix in 2022 and then received another dose of Menveo and Boostrix today (22-January-2025). The patient received Menveo at longer time than the recommended which led lengthening of vaccination schedule. The patient received Boostrix at shorter time than the recommended which led shortening of vaccination schedule. The reporter consented to follow up.